Monitoring Gesetzessammlung

Gesetze und Verordnungen USA alphabetisch

§ 355–1 - Risk evaluation and mitigation strategies
21 USC 355–1
§ 355–2 - Actions for delays of generic drugs and biosimilar biological products
21 USC 355–2
§ 356 - Expedited approval of drugs for serious or life-threatening diseases or conditions
21 USC 356
§ 356a - Manufacturing changes
21 USC 356a
§ 356b - Reports of postmarketing studies
21 USC 356b
§ 356c - Discontinuance or interruption in the production of life-saving drugs
21 USC 356c
§ 356c–1 - Annual reporting on drug shortages
21 USC 356c–1
§ 356d - Coordination; task force and strategic plan
21 USC 356d
§ 356e - Drug shortage list
21 USC 356e
§ 356f - Hospital repackaging of drugs in shortage
21 USC 356f
§ 356g - Standards for regenerative medicine and regenerative advanced therapies
21 USC 356g
§ 356h - Competitive generic therapies
21 USC 356h
§ 356i - Prompt reports of marketing status
21 USC 356i
§ 356j - Discontinuance or interruption in the production of medical devices
21 USC 356j
§ 356k - Platform technologies
21 USC 356k
§ 356l - Advanced manufacturing technologies designation program
21 USC 356l
§ 356–1 - Accelerated approval of priority countermeasures
21 USC 356–1
§ 356–2 - Accelerated approval Council
21 USC 356–2
§ 357 - Qualification of drug development tools
21 USC 357
§ 358 - Authority to designate official names
21 USC 358
Verwendung von Cookies.

Durch die Nutzung dieser Website akzeptieren Sie automatisch, dass wir Cookies verwenden. Cookie-Richtlinie

Akzeptieren
Markierungen
Leseansicht